In locally advanced, unresectable stage III EGFRm NSCLC following concurrent or sequential CRT TAGRISSO demonstrated
an almost sevenfold increase
TAGRISSO demonstrated an almost sevenfold increase in median PFS following CRT

˜7x

mPFS benefit

39.1 months (95% CI: 31.5, NE) with TAGRISSO vs
5.6 months (95% CI:
3.7, 7.4) with placebo per
blinded independent central review (BICR);
HR=0.16 (95% CI: 0.10, 0.24); P<0.001; N=2161*
LOCALLY ADVANCED, UNRESECTABLE EGFRm NSCLC

*Primary endpoint in LAURA.1